Related Experiment Video
Updated: Jun 6, 2025
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations
Published on: January 7, 2019
Is transcutaneous auricular vagus nerve stimulation effective and safe for primary insomnia? A PRISMA-compliant
Ting Yang1, Yunhuo Cai2, Xingling Li3
1Department of Nursing, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou City, China.
Background:
Insomnia is a highly prevalent sleep disorder with substantial impacts on health and quality of life. Current treatment options have certain limitations, highlighting the need for novel therapeutic approaches. Transcutaneous auricular vagus nerve stimulation (ta-VNS) is gaining recognition as a promising non-invasive neuromodulation technique for treating insomnia, but its efficacy has not been systematically evaluated. Therefore, this protocol outlines the framework for a systematic review and meta-analysis designed to comprehensively assess the effectiveness and safety of ta-VNS in treating primary insomnia.
Methods:
A thorough literature search will be carried out in Embase, PubMed, the Cochrane Library, PsycINFO, AMED, PEDro, Wangfang database, Chinese National Knowledge Infrastructure, and Chinese BioMedical Literature Database, covering publications from their inception until December 31, 2024. Randomized controlled trials evaluating ta-VNS for primary insomnia in adults will be included. Two independent reviewers will screen studies, gather data, and evaluate the risk of bias based on the Cochrane RoB 2.0 tool. Meta-analyses will be conducted where appropriate, and the quality of evidence will be evaluated using GRADE. Subgroup and sensitivity analyses are planned.
Discussion:
This systematic review and meta-analysis will deliver a thorough synthesis of existing evidence regarding the efficacy and safety of ta-VNS for insomnia, potentially informing clinical practice and future research directions.
Trial Registration:
PROSPERO registration number: CRD42024529039.
Related Concept Videos
01:19Management of Insomnia
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...